XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Apr. 18, 2022
Apr. 30, 2022
Jun. 30, 2016
May 31, 2016
Sep. 30, 2022
Sep. 30, 2022
Jun. 30, 2023
Dec. 31, 2021
Oct. 31, 2018
Sep. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Acquisitions                        
Goodwill         $ 3,467,748 $ 3,467,748            
Pelican Therapeutics, Inc.                        
Acquisitions                        
Ownership interest in subsidiary         85.00% 85.00%   85.00% 85.00% 80.00%    
Pelican Therapeutics, Inc.                        
Acquisitions                        
Percentage of voting interests acquired in acquisition                       80.00%
Amount awarded from CPRIT grant       $ 15,200,000                
Pelican Therapeutics, Inc. | Grant revenue | Maximum                        
Acquisitions                        
Amount awarded from CPRIT grant     $ 15,200,000                  
Pelican Therapeutics, Inc. | Certain Directors                        
Acquisitions                        
Percentage of milestone payments that will be paid to related parties                     22.70%  
Elusys Therapeutics                        
Acquisitions                        
Acquisition costs         $ 5,000.0 $ 600,000            
Earn out payments period 12 years                      
Percentage of earn out payments 10.00%                      
Frequency of periodic earn out payment 1 year                      
Period of occurrence of earn payment 9 years                      
Receivable consideration $ 22,318,685                      
Consideration paid   $ 20,800,000                    
Contract receivables 24,526,232                      
Fair value of the purchase consideration 42,900,000                      
Cash consideration 3,000,000                      
Deferred cash consideration 2,000,000                      
Fair value of contingent and deferred consideration liabilities $ 37,900,000                      
Discount rate for deferred consideration 24.00%                      
Discount rate for earn out liabilities 14.00%                      
Preliminary value of Additional Earn Out liability as percentage 80.00%                      
Goodwill $ 3,467,748                      
Goodwill deductible for tax purposes 15 years                      
Elusys Therapeutics | Forecast                        
Acquisitions                        
Contingent consideration             $ 4,700,000